These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9658642)

  • 1. [Treatment of erectile dysfunction using intracavernous pharmacotherapy].
    Rodríguez Vela L; Moncada Iribarren I; Gonzalvo Ibarra A; Sáenz de Tejada y Gorman I
    Actas Urol Esp; 1998 Apr; 22(4):291-319. PubMed ID: 9658642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Response to intracavernous administration of 3 different drugs in the same group of patients with erectile dysfunction].
    Ribé N; Rajmil O; Bassas L; Jurado C; Pomerol JM
    Arch Esp Urol; 2001 May; 54(4):355-9. PubMed ID: 11455770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracavernous chlorpromazine versus phentolamine: a double-blind clinical comparative study.
    Shamloul R; El-Dakhly M; Ghanem H; Gadallah A; Mokhtar H
    J Sex Med; 2004 Nov; 1(3):310-3. PubMed ID: 16422961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prostaglandin E1 in erectile dysfunction].
    Porst H
    Urologe A; 1989 Mar; 28(2):94-8. PubMed ID: 2655258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term results of the treatment with intracavernous injection of vasoactive drugs].
    Rodríguez Vela L; Gonzalvo Ibarra A; Gil Martínez P; Benejan Gual J; Cuesta Presedo JM; Ríoja Sanz LA
    Arch Esp Urol; 1996 Apr; 49(3):257-69. PubMed ID: 8702347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
    Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
    Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erectile dysfunction: intracavernous treatment.
    Ledda A
    Curr Med Res Opin; 2000; 16 Suppl 1():s59-62. PubMed ID: 11329824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1.
    Seyam R; Mohamed K; Akhras AA; Rashwan H
    Int J Impot Res; 2005; 17(4):346-53. PubMed ID: 15772683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
    Vardi Y; Lidgi S; Moskovitz B; Levin RD
    Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Endocavernous drug infusions revisited].
    Bellorofonte C; Ruoppolo M; Dell'Acqua S; Zaatar C; Ferri PM; Yamak R; Tagliaferri A; Tombolini P
    Arch Ital Urol Nefrol Androl; 1991 Dec; 63(4):475-9. PubMed ID: 1838835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances.
    Moemen MN; Hamed HA; Kamel II; Shamloul RM; Ghanem HM
    Int J Impot Res; 2004 Apr; 16(2):143-5. PubMed ID: 15014552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasoactive cocktails for erectile dysfunction: chemical stability of PGE1, papaverine and phentolamine.
    Soli M; Bertaccini A; Carparelli F; Gotti R; Cavrini V; Andrisano V; Martorana G
    J Urol; 1998 Aug; 160(2):551-5. PubMed ID: 9679927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracavernous pharmacotherapy: comparison of Moxisylyte and prostaglandin E1.
    Buvat J; Lemaire A; Herbaut-Buvat M
    Int J Impot Res; 1996 Jun; 8(2):41-6. PubMed ID: 8858388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and therapeutic technology assessment. Vasoactive intracavernous pharmacotherapy for impotence: intracavernous injection of prostaglandin E1.
    JAMA; 1991 Jun; 265(24):3321-3. PubMed ID: 2046116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracavernous sodium nitroprusside (SNP) versus papaverine/phentolamine in erectile dysfunction: a comparative study of short-term efficacy and side-effects.
    Shamloul R; Atteya A; Elnashaar A; Gadallah A; Zohdy W; Abdelsalam W
    J Sex Med; 2005 Jan; 2(1):117-20. PubMed ID: 16422914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Test with intracavernous injection of PGE1 in erectile dysfunction: our experience].
    Domínguez Domínguez M; Amaya Gutiérrez J; Blasco Hernández P; Vega Toro P; Alonso Flores J; García Pérez M
    Actas Urol Esp; 2000; 24(10):796-800. PubMed ID: 11199295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience.
    Porst H
    J Urol; 1996 Mar; 155(3):802-15. PubMed ID: 8583582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy.
    Raina R; Lakin MM; Agarwal A; Ausmundson S; Montague DK; Zippe CD
    Urology; 2004 Mar; 63(3):532-7; discussion 538. PubMed ID: 15028452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Percutaneous use of vasoactive drugs in the diagnosis and treatment of erectile impotence].
    Pastorini S; Marino G; Cocimano V; Marten Perolino R
    Minerva Urol Nefrol; 1992; 44(3):191-3. PubMed ID: 1492270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.